In this article (Clin Cancer Res 2014;20:76–86), which was published in the January 1, 2014, issue of Clinical Cancer Research (1), an error occurred during the assembly of the final Fig. 5A that resulted in the publication of an incorrect representative animal image. The correct Fig. 5A is shown below. The authors state that this clarification does not change the results, scientific content, interpretations, or conclusions of the article. The authors regret this error.

Figure 5.

A, alisertib exhibits antitumor activity, suppresses HDM2, and enhances P53 function in vivo. AGS cancer cells were injected in the flanks of 10 female nude mice. The treatment group received alisertib (30 mg/kg) for 21 days. Tumor size was measured every 4 days. The data indicated that alisertib has significant antitumor activity against AGS xenografts; **, P < 0.01. The frozen tissues samples available from the bio-banked tumor xenograft repository of this experiment were used for the experiments shown in panels B, C, and D.

Figure 5.

A, alisertib exhibits antitumor activity, suppresses HDM2, and enhances P53 function in vivo. AGS cancer cells were injected in the flanks of 10 female nude mice. The treatment group received alisertib (30 mg/kg) for 21 days. Tumor size was measured every 4 days. The data indicated that alisertib has significant antitumor activity against AGS xenografts; **, P < 0.01. The frozen tissues samples available from the bio-banked tumor xenograft repository of this experiment were used for the experiments shown in panels B, C, and D.

Close modal
1.
Sehdev
V
,
Katsha
A
,
Arras
J
,
Peng
D
,
Soutto
M
,
Ecsedy
J
, et al
HDM2 regulation by AURKA promotes cell survival in gastric cancer
.
Clin Cancer Res
2014
;
20
:
76
86
.